AInvest★★★★★3-DAY FREE
Catch pre-market movers with AI signals.
Claim Trial
TECH
Bio-Techne·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 3
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TECH
Bio-Techne Corporation
A leading developer and manufacturer of biotechnology reagents and instruments for research, diagnostics, and pharmaceutical applications
Biotechnology Ⅲ
07/17/1981
05/12/1989
NASDAQ Stock Exchange
3,000
06-30
Common stock
614 McKinley Place N.E., Minneapolis, MN 55413
Develops, manufactures and sells life science reagents, instruments and services.
Bio-Techne Corporation was founded in Minnesota on July 17, 1981. Bio-Techne and its subsidiaries jointly operate businesses that develop, manufacture and sell life science reagents, instruments and services for the global research, diagnostic and bioprocessing markets. With its deep product portfolio and applied expertise, the company sells components of scientific investigations of biological processes and molecular diagnosis, revealing the nature, diagnosis, etiology and progression of specific diseases.
Company Financials
EPS
TECH has released its 2026 Q4 earnings. EPS was reported at 0.52, versus the expected 0.52, meeting expectations. The chart below visualizes how TECH has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TECH has released its 2026 Q4 earnings report, with revenue of 321.19M, reflecting a YoY change of 1.33%, and net profit of 54.62M, showing a YoY change of 409.00%. The Sankey diagram below clearly presents TECH's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
